aspirin has been researched along with Aortic Diseases in 32 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 9.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 9.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2." | 9.09 | Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. ( Asinger, R; Blackshear, JL; Fenster, P; Halperin, J; Pearce, LA; Pennock, G; Strauss, R; Zabalgoitia, M, 1999) |
| "Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin." | 5.30 | Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 5.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 5.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "The relationship between arch plaques and recurrent events was studied in 516 patients with ischemic stroke who were double-blindly randomized to treatment with warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-Aspirin Recurrent Stroke Study (WARSS)." | 5.14 | Aortic arch plaques and risk of recurrent stroke and death. ( Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Russo, C; Sacco, RL, 2009) |
| "Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2." | 5.09 | Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. ( Asinger, R; Blackshear, JL; Fenster, P; Halperin, J; Pearce, LA; Pennock, G; Strauss, R; Zabalgoitia, M, 1999) |
| "The diagnosis of thoracic aortic mobile thrombus (TAMT) is rare and is usually made after debilitating embolic events." | 1.37 | Thoracic aortic mobile thrombus: is there a role for early surgical intervention? ( Ganzel, BL; Kapoor, N; Pagni, S; Ross, C; Slater, AD; Trivedi, J; Williams, M, 2011) |
| "Spontaneous aortic thrombosis is rare." | 1.35 | Aortic thrombosis in infancy. ( Mehta, AV; Teixeira, OH, 2009) |
| "Aspirin treatment had no significant effect on the neointimal smooth muscle component, but partially inhibited macrophage infiltration, without inhibiting ICAM-1 expression." | 1.33 | S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. ( Berry, CL; Campbell, JH; Thomas, AC; Worth, NF, 2005) |
| "Aortic thrombus formation is rare in the patients with essential thrombocytosis (ET); therefore, no guidelines for its management have been established." | 1.31 | Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. ( Agha, S; Cleary, JP; Fang, M; Lee, R; Lockridge, L; Mazur, EM, 2001) |
| "Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin." | 1.30 | Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (28.13) | 18.7374 |
| 1990's | 8 (25.00) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 7 (21.88) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| King, RW | 1 |
| Dias, AP | 1 |
| MukherJee, RD | 1 |
| Genovese, EA | 1 |
| Veeraswamy, RK | 1 |
| Wooster, MD | 1 |
| Amarenco, P | 2 |
| Albers, GW | 2 |
| Denison, H | 1 |
| Easton, JD | 1 |
| Evans, SR | 1 |
| Held, P | 1 |
| Hill, MD | 1 |
| Jonasson, J | 1 |
| Kasner, SE | 1 |
| Ladenvall, P | 1 |
| Minematsu, K | 1 |
| Molina, CA | 1 |
| Wang, Y | 1 |
| Wong, KSL | 1 |
| Johnston, SC | 1 |
| Davis, S | 1 |
| Jones, EF | 1 |
| Cohen, AA | 1 |
| Heiss, WD | 1 |
| Kaste, M | 1 |
| Laouénan, C | 1 |
| Young, D | 1 |
| Macleod, M | 1 |
| Donnan, GA | 1 |
| George, PM | 1 |
| Di Tullio, MR | 1 |
| Russo, C | 1 |
| Jin, Z | 1 |
| Sacco, RL | 1 |
| Mohr, JP | 1 |
| Homma, S | 1 |
| Teixeira, OH | 1 |
| Mehta, AV | 1 |
| Bhindi, R | 1 |
| Ormerod, OJ | 1 |
| Schmidt, T | 1 |
| Tsakiris, DA | 1 |
| Grapow, M | 1 |
| Siegemund, M | 1 |
| Pagni, S | 1 |
| Trivedi, J | 1 |
| Ganzel, BL | 1 |
| Williams, M | 1 |
| Kapoor, N | 1 |
| Ross, C | 1 |
| Slater, AD | 1 |
| Bötticher, G | 1 |
| Gäbel, G | 1 |
| Weiss, N | 1 |
| Saeger, HD | 1 |
| Bergert, H | 1 |
| Avegliano, G | 1 |
| Evangelista, A | 1 |
| Elorz, C | 1 |
| González-Alujas, T | 1 |
| García del Castillo, H | 1 |
| Soler-Soler, J | 1 |
| Worth, NF | 1 |
| Berry, CL | 1 |
| Thomas, AC | 1 |
| Campbell, JH | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Perugini, E | 1 |
| Pallotti, MG | 1 |
| Pavesi, PC | 1 |
| Di Pasquale, G | 1 |
| Leffert, RL | 1 |
| Hackett, RL | 1 |
| Hagen, PO | 1 |
| Wang, ZG | 1 |
| Mikat, EM | 1 |
| Hackel, DB | 1 |
| Schaub, RG | 1 |
| Gates, KA | 1 |
| Roberts, RE | 1 |
| Ricou, FJ | 1 |
| Arroyo, JF | 1 |
| Manning, WJ | 1 |
| Iomhair, MM | 1 |
| Lavelle, SM | 1 |
| Blackshear, JL | 1 |
| Zabalgoitia, M | 1 |
| Pennock, G | 1 |
| Fenster, P | 1 |
| Strauss, R | 1 |
| Halperin, J | 1 |
| Asinger, R | 1 |
| Pearce, LA | 1 |
| Poliantsev, AA | 1 |
| Spasov, AA | 1 |
| Mozgovoĭ, PV | 1 |
| Karpenko, AV | 1 |
| Shcherbakov, VN | 1 |
| Kuznetsov, VI | 1 |
| Khomutnikova, AI | 1 |
| Kirichenko, OM | 1 |
| Fang, M | 1 |
| Agha, S | 1 |
| Lockridge, L | 1 |
| Lee, R | 1 |
| Cleary, JP | 1 |
| Mazur, EM | 1 |
| Pick, R | 1 |
| Chediak, J | 1 |
| Glick, G | 1 |
| Pokrovskiĭ, AV | 2 |
| Dmitrieva, VA | 1 |
| Aleksandrova, NP | 2 |
| Kovalenko, VI | 2 |
| Il'in, SG | 1 |
| Scriven, AJ | 1 |
| Lidbury, PS | 1 |
| Nathan, AW | 1 |
| Fuster, V | 1 |
| Badimon, L | 1 |
| Badimon, JJ | 1 |
| Ip, JH | 1 |
| Chesebro, JH | 1 |
| Függer, R | 1 |
| Prager, M | 1 |
| Sautner, T | 1 |
| Kretschmer, G | 1 |
| Polterauer, P | 1 |
| Lewin, J | 1 |
| Swedenborg, J | 1 |
| Egberg, N | 1 |
| Vesterqvist, O | 1 |
| Green, K | 1 |
| Pion, PD | 1 |
| Pujadas, R | 1 |
| Escrivá, E | 1 |
| Fernández, F | 1 |
| Jané, J | 1 |
| Argimón, J | 1 |
| Fava, P | 1 |
| Galera, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248] | Phase 3 | 350 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151] | Phase 4 | 630 participants (Actual) | Interventional | 1993-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
5 reviews available for aspirin and Aortic Diseases
| Article | Year |
|---|---|
[Antithrombotic therapy after peripheral vascular treatment: what is evidence-based?].
Topics: Aortic Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dose-Response Relations | 2012 |
[Atheromatosis of the thoracic aorta and risk of stroke].
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled | 2006 |
[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin].
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiomyopath | 1996 |
Role of transesophageal echocardiography in the management of thromboembolic stroke.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Cerebrovascular Disorde | 1997 |
The porcine model for the understanding of thrombogenesis and atherogenesis.
Topics: Angioplasty, Balloon, Coronary; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary | 1991 |
7 trials available for aspirin and Aortic Diseases
| Article | Year |
|---|---|
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia; | 2014 |
Aortic arch plaques and risk of recurrent stroke and death.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Death; D | 2009 |
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Drug Therapy, | 1998 |
Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography.
Topics: Aged; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillati | 1999 |
[Blood rheological disorders in atherosclerotic lesion of the abdominal aorta and their correction by the use of aspirin].
Topics: Adult; Aged; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Circulation; Clinic | 1979 |
[Synthetic vascular reconstructions in the pelvis: function and survival].
Topics: Aortic Diseases; Arterial Occlusive Diseases; Aspirin; Blood Vessel Prosthesis; Combined Modality Th | 1990 |
20 other studies available for aspirin and Aortic Diseases
| Article | Year |
|---|---|
Staging Endovascular Thoracic and Thoracoabdominal Aortic Aneurysm Repairs and the Risk of Post-operative Spinal Cord Ischemia.
Topics: Aortic Aneurysm, Thoracic; Aortic Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Endovascu | 2022 |
Aortic arch atheroma: a plaque of a different color or more of the same?
Topics: Anticoagulants; Aortic Diseases; Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation In | 2014 |
Aortic thrombosis in infancy.
Topics: Anticoagulants; Aortic Diseases; Aspirin; Echocardiography, Doppler; Enoxaparin; Female; Humans; Inf | 2009 |
Letter by Bhindi and Ormerod regarding article, "Aortic arch plaques and risk of recurrent stroke and death".
Topics: Anticoagulants; Aortic Diseases; Aspirin; Atherosclerosis; Fibrinolytic Agents; Humans; Hydroxymethy | 2010 |
[Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].
Topics: ADAM Proteins; ADAMTS13 Protein; Aged, 80 and over; Aortic Diseases; Aspirin; Coma; Critical Care; D | 2011 |
Thoracic aortic mobile thrombus: is there a role for early surgical intervention?
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Aortic Diseases; Aspirin; Echocardiography, Transes | 2011 |
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv | 2002 |
S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits.
Topics: Animals; Aortic Diseases; Aspirin; Atherosclerosis; Catheterization; Diet, Atherogenic; Drug Evaluat | 2005 |
Aspergillus aortitis following replacement of aortic valve.
Topics: Adult; Aortic Diseases; Aspergillus; Aspirin; Cardiac Catheterization; Cephalothin; Extracorporeal C | 1967 |
Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyr | 1982 |
Effect of aspirin on collateral blood flow after experimental thrombosis of the feline aorta.
Topics: Animals; Aortic Diseases; Aspirin; Cat Diseases; Cats; Collateral Circulation; Hindlimb; Platelet Ag | 1982 |
Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal.
Topics: Animals; Aortic Diseases; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Rats; Rats, S | 1998 |
[Prevention of early thrombotic complications after reconstructive operations in occlusions of the aorto-iliac segment].
Topics: Adult; Aged; Anticoagulants; Aorta, Abdominal; Aortic Diseases; Arterial Occlusive Diseases; Aspirin | 2000 |
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia.
Topics: Aorta, Abdominal; Aortic Diseases; Aspirin; Biopsy, Needle; Drug Therapy, Combination; Female; Follo | 2001 |
Aspirin inhibits development of coronary atherosclerosis in cynomolgus monkeys (Macaca fascicularis) fed an atherogenic diet.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary Disease; Diet, Atherogenic; Haplorhini | 1979 |
[Correction of disorders of rheologic properties of blood in reconstructive operations on the abdominal aorta].
Topics: Adult; Aged; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Viscosity; Dipyrida | 1978 |
Effects of laser-generated tissue debris on aggregation of human platelets.
Topics: Aged; Angioplasty, Laser; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Coagulat | 1991 |
Effect of acetyl salicylic acid on increased production of thromboxane after aortic graft surgery.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm; Aortic Diseases; Arterial Occlusive Diseases; Aspirin; Bloo | 1989 |
Feline aortic thromboemboli: t-PA thrombolysis followed by aspirin therapy and rethrombosis.
Topics: Animals; Aortic Diseases; Aspirin; Cat Diseases; Cats; Female; Recurrence; Thromboembolism; Tissue P | 1988 |
[Effect of various doses of aspirin on the development of aseptic thrombotic aortic endocarditis experimentally induced in the rabbit].
Topics: Animals; Aortic Diseases; Aspirin; Cardiac Catheterization; Disease Models, Animal; Dose-Response Re | 1988 |